Cardiovascular Today—March 5, 2026

This week’s Cardiovascular update highlights regulatory clearances, late-stage heart failure data, structural heart durability insights, and emerging device-based hypertension therapies.

In Today’s Newsletter

Dive deeper

🧬 BioCardia CardiAMP shows Phase III remodelling signal in ischaemic HFrEF [1] [US • 04 Mar 2026]

https://cardiovascularnews.com/tht-2026-autologous-cell-therapy-may-curb-pathological-ventricular-remodelling-in-chronic-ischaemic-hfref-patients/
Context: BioCardia presented late-breaking Phase III CardiAMP HF echocardiography data at THT 2026 in Boston.
Key point: BioCardia said autologous CardiAMP was associated with decreased pathological left ventricular remodelling versus control, and the findings aligned with previously reported primary and key secondary endpoints.
Implication: May influence prescriber choice and payer reviews pending full data.

🫀 Medtronic Evolut Low Risk shows higher late reintervention after TAVI [2] [US • 02 Mar 2026]

https://cardiovascularnews.com/evolut-low-risk-investigators-probe-increasing-reintervention-rate-beyond-six-years/
Context: The randomised Evolut Low Risk trial enrolled 1,414 low-surgical-risk patients, comparing Medtronic Evolut TAVI with surgical aortic valve replacement.
Key point: Six-year data, plus a post-hoc analysis through seven years, showed reintervention rose more after TAVI than surgery, with regurgitation-related reinterventions more frequent in the TAVI arm.
Implication: May influence heart-team decisions on valve choice, follow-up imaging, and procedural technique.

💧 Relief Cardiovascular reports first-in-human decongestion implant data [3] [04 Mar 2026]

https://cardiovascularnews.com/tht-2026-study-of-smart-implant-for-heart-failure-decongestion-reports-first-in-human-data/
Context: RELIEF-FIH was a prospective, multicentre first-in-human study with eight participants across three European sites, with 90-day follow-up.
Key point: Relief Cardiovascular said the study met endpoints for procedural safety, sustained on-demand renal vein flow, and automatic haemodynamic pressure measurement accuracy.
Implication: May influence prescriber choice and payer reviews pending full data.

📡 Abbott CardioMEMS HERO gains FDA approval [4] [US • 02 Mar 2026]

https://cardiovascularnews.com/abbotts-next-generation-pa-pressure-reader-gains-us-fda-approval/
Context: CardioMEMS HERO is the next-generation reader for Abbott’s CardioMEMS HF system, used with the implanted PA pressure sensor.
Key point: Abbott said the FDA approved CardioMEMS HERO, and US commercial release will begin soon.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🇯🇵 Recor Medical Paradise uRDN becomes reimbursed in Japan [5] [Japan • 02 Mar 2026]

https://cardiovascularnews.com/paradise-renal-denervation-system-available-in-japan/
Context: Otsuka Medical Devices said National Health Insurance coverage took effect on 01 Mar 2026, with sales starting on 02 Mar 2026.
Key point: Recor Medical’s Paradise ultrasound renal denervation system is now available in Japan for resistant hypertension under reimbursement.
Implication: Introduces competition that may affect pricing and formulary access.

👩‍⚕️ Coronary plaque burden threshold for MACE appears lower in women [6] [02 Mar 2026]

https://www.clinicaladvisor.com/news/major-adverse-cardiovascular-risk-lower-coronary-plaque-burden-in-women/
Context: A Circulation analysis included 4,267 patients with stable chest pain, with median follow-up of 26 months.
Key point: Women had lower plaque volume, but major adverse cardiovascular event risk became elevated at lower plaque burden levels than in men.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🏥 NIHR backs new UK consortium on cardiovascular inequality [7] [UK • 02 Mar 2026]

https://www.nationalhealthexecutive.com/articles/nihr-launches-new-consortium-tackle-cardiovascular-disease-inequality
Context: NIHR and the British Heart Foundation are funding a nine-university consortium with £50 million, with first projects due to begin in autumn 2026.
Key point: The consortium will focus on cardiovascular disease inequalities, especially undiagnosed or poorly managed high blood pressure, high LDL cholesterol, and sex-based gaps in outcomes.
Implication: May expand screening, initiation, and follow-up at scale.

🔌 Orchestra BioMed highlights AVIM Therapy potential in hypertension and heart failure [8] [US • 03 Mar 2026]

https://finance.yahoo.com/news/orchestra-biomed-announces-presentations-highlighting-130000155.html
Context: Orchestra BioMed announced THT and CRT 2026 presentations on AVIM Therapy, an investigational pacemaker-compatible therapy.
Key point: The company said pilot and mechanistic data suggest sustained systolic blood pressure reduction and potential relevance for hypertensive heart disease and diastolic dysfunction, while the BACKBEAT pivotal study continues.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Heart failure innovation is broadening, from monitoring upgrades to active decongestion implants and regenerative approaches [1][3][4].
Long-term durability is becoming a more visible issue in low-risk structural heart intervention [2].
Resistant hypertension treatment options are expanding, with renal denervation access improving in Japan and implant-based approaches still advancing [5][8].
Sex-specific imaging risk signals could shift how coronary disease burden is interpreted in practice [6].
Public-sector research funding is increasingly focused on prevention and access gaps, not only treatment [7].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cardiovascular archive on our research hub page

FAQ

What is new in the BioCardia CardiAMP update?

BioCardia reported late-breaking Phase III echocardiography data showing less adverse left ventricular remodelling in treated patients versus control. The source also described stronger subgroup findings in patients with elevated NT-proBNP. [1]

Why is the Evolut Low Risk readout important?

It adds longer-term durability detail in low-risk patients. The study showed higher reintervention after TAVI than surgery over six to seven years, with regurgitation-related events contributing to the gap. [2]

How early is the Relief Cardiovascular dataset?

It is very early. RELIEF-FIH is a first-in-human study with eight patients and 90-day follow-up, so the findings are promising but still based on a small dataset. [3]

Is CardioMEMS HERO a new implant?

No. It is a new reader for Abbott’s existing CardioMEMS HF system. The implanted PA sensor remains the monitoring component, while HERO is the updated external reader. [4]

What changed for Paradise uRDN in Japan?

The key step is reimbursement. Japan’s National Health Insurance now covers the system, and Otsuka Medical Devices has started sales, which should improve access for eligible resistant hypertension patients. [5]

What is AVIM Therapy designed to do?

AVIM Therapy is an investigational pacemaker-compatible therapy designed to lower blood pressure by modulating the atrioventricular interval. Orchestra BioMed is also presenting data that frame it as relevant to hypertensive heart disease and diastolic dysfunction. [8]

Entities / Keywords

BioCardia CardiAMP: CardiAMP HF, autologous cell therapy, ischaemic heart failure, HFrEF
Medtronic Evolut: Evolut Low Risk, TAVI, SAVR, aortic regurgitation, valve durability
Relief Cardiovascular Relief System: RELIEF-FIH, decongestion implant, renal vein flow, venous haemodynamics
Abbott CardioMEMS HERO: CardioMEMS HF system, PA pressure reader, heart failure monitoring
Recor Medical Paradise uRDN: ultrasound renal denervation, resistant hypertension, Otsuka Medical Devices
Coronary plaque burden study: Circulation, stable chest pain, sex differences, MACE
NIHR CVD Inequalities Challenge Consortium: British Heart Foundation, hypertension, LDL cholesterol, health inequalities
Orchestra BioMed AVIM Therapy: BACKBEAT, pacemaker-based hypertension therapy, hypertensive heart disease, HFpEF